# Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

*PRI Rank #14 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-14*

| Field | Value |
| --- | --- |
| Rank | #14 |
| 18m citations | 123 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-02894-y |
| Corresponding authors | Mark Yarchoan, Niranjan Y. Sardesai |
| Institution | Johns Hopkins University, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1038/s41591-024-02894-y](https://doi.org/10.1038/s41591-024-02894-y)

## Topics

hepatocellular carcinoma · personalized neoantigen vaccine · pembrolizumab · PD-1 inhibition · GNOS-PV02 · DNA plasmid vaccine · interleukin-12 · Tyrosine kinase inhibitor · neoantigen-specific T cell responses · Enzyme-linked immunosorbent spot assay · CD4+ effector T cells · CD8+ effector T cells · T cell receptor β-chain sequencing · vaccine-enriched T cell clone expansion · immune cell infiltration · single-cell analysis · cytotoxic T cell phenotypes · TCR complementarity-determining region cloning · Objective response rate (ORR) · complete response

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```